Comparative Pharmacology
Head-to-head clinical analysis: CARBATROL versus LAMOTRIGINE.
Head-to-head clinical analysis: CARBATROL versus LAMOTRIGINE.
CARBATROL vs Lamotrigine
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilizes neuronal membranes by blocking voltage-gated sodium channels, inhibiting repetitive firing of action potentials. Also enhances GABAergic activity.
Stabilizes neuronal membranes by blocking voltage-gated sodium channels and inhibiting the release of excitatory neurotransmitters, particularly glutamate and aspartate.
Initial dose 200 mg orally twice daily, increase by 200 mg/day at weekly intervals; maintenance 800-1200 mg/day in 2 divided doses extended-release capsules.
Initial: 25 mg orally once daily for 2 weeks, then 50 mg once daily for 2 weeks, then increase by 50 mg every 1-2 weeks. Maintenance: 100-200 mg twice daily (200-400 mg/day). Maximum: 400 mg/day.
None Documented
None Documented
Clinical Note
moderateLamotrigine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Lamotrigine is combined with Fluticasone propionate."
Clinical Note
moderateLamotrigine + Desmopressin
"The risk or severity of adverse effects can be increased when Lamotrigine is combined with Desmopressin."
Clinical Note
moderateLamotrigine + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Lamotrigine."
Clinical Note
moderateLamotrigine + Fluconazole
Terminal elimination half-life 25-65 hours initially, then 12-17 hours after autoinduction; clinical context: requires dose adjustment after 3-5 weeks.
25.4 h (range 24-31 h, prolonged to 59 h with valproate)
Renal: 70% as metabolites (including carbamazepine-10,11-epoxide) and 2-3% as unchanged drug; biliary/fecal: 30%.
Renal (94% as metabolites, 10% unchanged; 2% fecal)
Category C
Category A/B
Anticonvulsant
Anticonvulsant
"The serum concentration of Fluconazole can be increased when it is combined with Lamotrigine."